AVROBIO (NASDAQ:AVRO) Shares Up 1.6%

AVROBIO, Inc. (NASDAQ:AVRO)’s stock price rose 1.6% during mid-day trading on Monday . The stock traded as high as $1.25 and last traded at $1.24. Approximately 156,514 shares were traded during trading, a decline of 43% from the average daily volume of 272,440 shares. The stock had previously closed at $1.22.

AVROBIO Trading Up 1.6 %

The firm’s fifty day moving average price is $1.26 and its 200-day moving average price is $1.33. The company has a market cap of $55.63 million, a P/E ratio of -12.40 and a beta of 1.24.

Hedge Funds Weigh In On AVROBIO

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Private Advisor Group LLC bought a new stake in shares of AVROBIO during the third quarter valued at approximately $33,000. Aldebaran Capital LLC acquired a new stake in AVROBIO during the third quarter worth $724,000. Newtyn Management LLC bought a new stake in AVROBIO in the 3rd quarter valued at $3,080,000. Terrapin Asset Management LLC acquired a new position in shares of AVROBIO in the 3rd quarter valued at $861,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of AVROBIO during the 3rd quarter worth about $770,000. 62.63% of the stock is currently owned by institutional investors.

AVROBIO Company Profile

AVROBIO, Inc, a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease.